breast cancer cells

[Scientific Reports] A patient-derived scaffold model was evaluated as a testing platform for the endocrine therapies (Z)-4-Hydroxytamoxifen and fulvestrant as well as the CDK4/6-inhibitor palbociclib, monitoring the treatment responses in breast cancer cell lines MCF7 and T47D adapted to the patient-based microenvironments.

[Signal Transduction and Targeted Therapy] Investigators found that the nonclassical histocompatibility antigen HLA-G desensitized breast cancer cells to trastuzumab by binding to the natural killer cell receptor KIR2DL4.

[Cancer Research] Using a combination of in vivo and in vitro analyses in a novel PyMT-E2A conditional knockout mouse model and derived primary tumor cell lines, researchers reported an essential role of E2A in stemness, metastasis, and therapeutic resistance in breast cancer.

[npj Breast Cancer] Researchers utilized breast cancer patient-derived xenografts from the Mayo Breast Cancer Genome Guided Therapy Study to establish two immortalized, genomically unique breast cancer cell lines.

[Communications Biology] The authors investigated how the spatiotemporal receptor organization at the cell surface was modulated by biparatopic designed ankyrin repeat proteins (bipDARPins), which potently induced apoptosis in human epidermal growth factor receptor 2-addicted breast cancer cell lines.

[Cell Death & Disease] Researchers used Cell Counting Kit-8, colony formation, wound healing migration, Transwell invasion, and nude mouse xenograft assays to confirm the role of the lncRNA actin filament-associated protein 1 antisense RNA1 (AFAP1-AS1) in the proliferation, migration of TNBC cells in vitro and in vivo.